Product Information
CINACALCET HCL 30 MG TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $0.4114 per EA under NDC 65862083105. Its NADAC has been published 256 times since Nov 10, 2021.
FDA first approved this application on Mar 8, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862083105
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CINACALCET HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA206125FDA Approved
3/8/2018
TE Code
AB
On Market Since
6/25/2019
Pharmacological Classes
Price Statistics
The NADAC for CINACALCET HCL 30 MG TABLET has been published 256 times since Nov 10, 2021, and over the history we have for it it has declined 41.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4114 per EA |
|---|---|
| All-time high | $1.0501 (Feb 16, 2022) |
| All-time low | $0.2542 (Nov 20, 2024) |
| 52-week high | $0.4156 |
| 52-week low | $0.3573 |
| Median price | $0.3625 |
| Average price | $0.4348 |
| Largest weekly change | -58.1% (Sep 21, 2022) |
| Weeks tracked | 256 |
| Tracking since | Nov 10, 2021 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Cinacalcet market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcium-sensing Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CINACALCET HCL 30 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CINACALCET HCL 30 MG TABLET, manufactured by Aurobindo Pharma Limited, is $0.4114 per EA (NDC 65862083105), effective Sep 30, 2026.
How has the price of CINACALCET HCL 30 MG TABLET changed over time?
Over the history we have for it, the NADAC for CINACALCET HCL 30 MG TABLET has declined 41.3%. It has been tracked across 256 weekly CMS publications since Nov 10, 2021.
What are the highest and lowest recorded NADAC prices for CINACALCET HCL 30 MG TABLET?
Since Nov 10, 2021, the NADAC for CINACALCET HCL 30 MG TABLET has ranged from a low of $0.2542 (Nov 20, 2024) to a high of $1.0501 (Feb 16, 2022), with a median of $0.3625 per EA.
Are there cheaper alternatives to CINACALCET HCL 30 MG TABLET?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CINACALCET HCL 30 MG TABLET, is $0.4030 per EA — about 2% below CINACALCET HCL 30 MG TABLET.
Who manufactures CINACALCET HCL 30 MG TABLET?
CINACALCET HCL 30 MG TABLET (NDC 65862083105) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.